L. Mauriac

20.1k total citations · 6 hit papers
171 papers, 11.5k citations indexed

About

L. Mauriac is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, L. Mauriac has authored 171 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 83 papers in Cancer Research and 64 papers in Genetics. Recurrent topics in L. Mauriac's work include Breast Cancer Treatment Studies (77 papers), Cancer Treatment and Pharmacology (59 papers) and Estrogen and related hormone effects (58 papers). L. Mauriac is often cited by papers focused on Breast Cancer Treatment Studies (77 papers), Cancer Treatment and Pharmacology (59 papers) and Estrogen and related hormone effects (58 papers). L. Mauriac collaborates with scholars based in France, Belgium and United States. L. Mauriac's co-authors include J.F.R. Robertson, M. Durand, Ignace Vergote, Beat Thürlimann, Matthew J. Ellis, Gaëtan MacGrogan, Alan Webster, A. Avril, Stephen E. Jones and Jacques Bonneterre and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

L. Mauriac

164 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

2005 1.2k citations L. Mauriac, M. Tubiana-Hulin et al. profile →
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

2002 855 citations Joyce O’Shaughnessy, David Miles et al. Journal of Clinical Oncology profile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 790 citations Matthew J. Ellis, Andrew Coop et al. Journal of Clinical Oncology profile →
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

2007 693 citations Alan S. Coates, Aparna Keshaviah et al. Journal of Clinical Oncology profile →
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

2000 606 citations Beat Thürlimann, L. Mauriac et al. Journal of Clinical Oncology profile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 530 citations W. Eiermann, Antonio Llombart‐Cussac et al. Annals of Oncology profile →

Peers

Countries citing papers authored by L. Mauriac

Since Specialization

Citations

This map shows the geographic impact of L. Mauriac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Mauriac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Mauriac more than expected).

Fields of papers citing papers by L. Mauriac

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Mauriac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Mauriac. The network helps show where L. Mauriac may publish in the future.

Co-authorship network of co-authors of L. Mauriac

This figure shows the co-authorship network connecting the top 25 collaborators of L. Mauriac. A scholar is included among the top collaborators of L. Mauriac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Mauriac. L. Mauriac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity 2012 ·Breast Cancer Research and Treatment ·Maud Toulmonde, Nicolas Madranges, Véronique Brouste, (unknown), Gaëtan MacGrogan, M. Durand, Hervé Bonnefoi, L. Mauriac, Marc Debled	13
2	Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study 2010 ·The Oncologist ·Jean-Marc Extra, (unknown), Anne Vincent‐Salomon, T. Delozier, Pierre Kerbrat, (unknown), Jean‐Paul Guastalla, M. Spielmann, L. Mauriac, Jean-Louis Misset, Daniel Serin, Mario Campone, Christophe Hébert, (unknown), Loïc Bergougnoux, Frank Campana, Moïse Namer	92
3	Is it useful to detect lymphovascular invasion in lymph node‐positive patients with primary operable breast cancer? 2010 ·Cancer ·(unknown), Marc Debled, Gaëtan MacGrogan, Véronique Brouste, (unknown), Isabelle Soubeyran, C. Tunon de Lara, L. Mauriac, Isabelle de Mascarel	29
4	A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer 2008 ·Clinical Cancer Research ·Maïa Chanrion, Vincent Nègre, Hélène Fontaine, Nicolas Salvetat, Frédéric Bibeau, (unknown), L. Mauriac, Dionyssios Katsaros, Franck Molina, Charles Theillet, Jean-Marie Darbon	139
5	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial 2007 ·Journal of Clinical Oncology ·Henning T. Mouridsen, Aparna Keshaviah, Alan S. Coates, Manuela Rabaglio, Monica Castiglione‐Gertsch, Zhuoxin Sun, Beat Thürlimann, L. Mauriac, John Forbes, Robert Paridaens, Richard D. Gelber, Marco Colleoni, Ian Smith, Karen N. Price, Aron Goldhirsch	93
6	Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. 2007 ·PubMed ·M. Tubiana-Hulin, Véronique Becette, Ivan Bièche, L. Mauriac, Gilles Romieu, Frédéric Bibeau, Gaëtan MacGrogan, Hugues Bourgeois, P. Chollet, Rémy Defrance, Frédérique Spyratos	17
7	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial 2007 ·Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, (unknown), Aron Goldhirsch	106
8	[HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?]. 2006 ·PubMed ·Yazid Belkacémi, Joseph Gligorov, L. Mauriac, D. Azria	3
9	Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use Programme 2005 ·Cancer Treatment Reviews ·Guenther G. Steger, (unknown), Sérgio D. Simon, Aňa Lluch, (unknown), Bella Kaufman, Andrew Wardley, L. Mauriac	18
10	Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. 2003 ·PubMed ·Matthew J. Ellis, Andrew Coop, Baljit Singh, Tao Yu, Antonio Llombart‐Cussac, F. Jänicke, L. Mauriac, Erhard Quebe‐Fehling, Hilary A. Chaudri‐Ross, Dean B. Evans, William R. Miller	167
11	Standards, Options et Recommandations : cancers du sein infiltrants non métastatiques - 2e édition, mise à jour, version abrégée 2002 ·Bulletin du Cancer ·L. Mauriac, (unknown)	5
12	EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer 2002 ·Annals of Oncology ·Anne Hamilton, Laura Biganzoli, Robert E. Coleman, L. Mauriac, (unknown), Ahmad Awada, (unknown), L.V.A.M. Beex, Martine Piccart, (unknown), P.F. Bruning, Dominique de Valeriola	83
13	Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women 2002 ·Annals of Oncology ·L. Mauriac, Marc Debled, M. Durand, Anne Floquet, (unknown), Corinne Dagada, Nathalie Trufflandier, Gaëtan MacGrogan	23
14	Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer 2001 ·Annals of Oncology ·Joyce O’Shaughnessy, Joanne L. Blum, Vladimir Moiseyenko, Stephen E. Jones, David Miles, Diana Bell, R. Rosso, L. Mauriac, B Osterwalder, Hans Ulrich Burger, Siobhan Laws	258
15	Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881 1998 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), (unknown), L. Mauriac, (unknown), Corinne Veyret, J. Wildiers, Jacek Jassem, J Burghouts, M. Piccart, F Mignolet, Luc Duchateau	8
16	pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients 1996 ·British Journal of Cancer ·Isabelle Soubeyran, (unknown), Jean‐Michel Coindre, F. Bonichon, M. Durand, (unknown), L. Mauriac	56
17	7th EORTC Breast Cancer Working Conference, Bordeaux, France, September 10-13, 1996 1996 ·Pergamon Press eBooks ·L. Mauriac	1
18	A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer * 1996 ·European Journal of Cancer ·W. Jonat, Anthony Howell, Carl Blomqvist, W. Eiermann, Gerard Winblad, C. Tyrrell, L. Mauriac, Henri Roché, Steinar Lundgren, Richard Hellmund, M. Azab	207
19	Votre unité Hers Girou certifié Qualité ISO 9001 1986 ·Bulletin du Cancer ·L. Mauriac, M. Durand, (unknown), J Chauvergne	2
20	Thyroïdite d'Hashimoto et encéphalopathie myoclonique. Hypothèses pathogéniques. 1985 ·Revue Neurologique ·(unknown), (unknown), (unknown), Bernard Bioulac, (unknown), P Loiseau, L. Mauriac	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact